Autopsy report · NCT00350714

BreathID Multi-center HCV Liver Breath Test Study

“Due to FDA comments, protocol changed; new trial will be proposed shortly”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 7 months before it stopped.
• 75 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Meridian Bioscience, Inc.

Sponsor type

Industry

Conditions

Hepatitis C

Interventions

MBT and BreathID

Participants

75

Sites

5

Countries

Israel, United States

Trials that died the same way

• Optimized Caloric-proteic Nutrition in Septic and Septic Shock Patients
  “The protocol was modified substantially and will be resubmitted to Clinical Trial” (80% match in meaning)
• Pre-emptive Anakinra for Cytokine Event Reduction
  “The trial has been stopped pending FDA approval of modifications to the trial protocol.” (74% match in meaning)
• An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
  “Trial has been cancelled due to availability of new therapeutic options for patient population” (71% match in meaning)
• Angiotensin II vs. Vasopressin in Septic Shock
  “Funding and protocol changes. Replaced with new pilot trial.” (70% match in meaning)
• Electrical Impedence Tomography With ENLIGHT2100
  “Device received FDA approval” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.